甲状腺功能亢进症治疗方法的选择

陈丹云; 静进

甲状腺功能亢进症治疗方法的选择

陈丹云 , 静进

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 4: (228-231)

引用本文:

Citation:

甲状腺功能亢进症治疗方法的选择

陈丹云¹,
静进²

1. 510080 广州, 中山大学附属第一医院东山院区甲亢治疗中心;
2. 510089 广州, 中山大学公共卫生学院
中图分类号: R581.05

Hyperthyroidism: a review of the treatment options

CHEN Dan-yun¹,
JING Jin²

Center of Treatment for Hyperthyroidisin, Dongshan Division, The fast Affilicaed Hospitaly Sun Yat-sen University Guangzhou, 510080, China
CLC number: R581.05

摘要: 甲状腺功能亢进症(甲亢)的治疗方法主要有内科抗甲状腺药物、¹³¹I和手术治疗,三种治疗方法各有优势以及不足之处,因此,长期以来对甲亢患者治疗方法的选择存在争议,不同国家优先应用的方法也不尽相同。
- 甲状腺功能亢进症 /
- 丙硫氧嘧啶 /
- 甲巯咪唑 /
- 碘放射性同位素 /
- 甲状腺切除术 /
- 对比研究
Abstract: Hyperthyroidism is commonly treated with anti-thyroid medications, radioactive iodine, or surgery. Three kinds of treatments have their own advantages and disadvantages. Therefore, the treatment of hyperthyroidism is still controversial. With regard to the first:choice, strategies vary among different countries.
- Hyperthyroidism /
- Propylthiouracil /
- Methimazole /
- Iodine isotopes /
- Thyroidectomy /
- Comparative study
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	白耀. 甲状腺病学-基础与临床.北京:科学技术文献出版社,2003.244-636.
[2]	张承刚. 主编.甲状腺疾病核素治疗学.北京:原子能出版社,2003.166-349.
[3]	Bolanos F,Gonzalez-Ortiz M,Duron H,et al. Remission of Graves' hyperthyroidism treated with methimazole.Rev Invest Clin,2002,54(4):307-310.
[4]	Menendez E,Anda E,Barberia JJ,et al. Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease.Multicenter study in Northern Spain.Rev Clin Esp,2000,200(2):69-73.
[5]	Quadbeck B,Hoermann R,Roggenbuck U,et al. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.Thyroid,2005,15(9):1047-1054.
[6]	Cooper DS. Hyperthyroidism.Lancet,2003,362(9382):459-468.
[7]	Cooper DS. Antithyroid Drugs.N Engl J Med,2005,352(9):905-917.
[8]	Woeber KA. Methimazole-induced hepatotoxicity.Endocr Pract,2002,8(3):222-224.
[9]	高莹,赵明辉,叶华,等. 19例丙基硫氧嘧啶引起抗中性粒细胞胞浆抗体相关小血管炎的临床分析.中华内分泌代谢杂志,2006,22(2):124-126.
[10]	Gao Y,Zhao MH,Guo XH,et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies(ANCA) in Chinese patients with hyperthyroidism.Endocr Res,2004,(3002):205-213.
[11]	Guma M,Salinas I,Reverter JL,et al. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole.J Clin Endocrionl Metab,2003,88(5):2141-2146.
[12]	Streetman DD,Khanderia U. Diagnosis and treatment of Graves disease.Ann Pharmacother,2003,37(7-8):1100-1109.
[13]	Ginsberg J. Diagnosis and management of Graves' disease.CMAJ,2003,168(5):575-585.
[14]	Giovanella L,De Palma D,Ceriani L,et al. Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach.Clinical results. Radiol Med(Torino),2000,100(6):480-483.
[15]	Metso S,Jaatinen P,Huhtala H,et al. Long-term follow-up study of radioiodine treatment of hyperthyroidism.Clin Endocrinol(Oxf),2004,61(5):641-648.
[16]	Santos RB,Romaldini JH,Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease.Thyroid,2004,14(7):525-530.
[17]	康增寿,戴维信,杜永昌. ¹³¹I治疗儿童Graves'甲亢安全、有效.国外医学·放射医学核医学分册,2001,25(4):149-152.
[18]	Stocker DJ,Foster SS,Solomon BL,et al. Thyroid cancer yield in patients with Graves' disease selected for surgery on the basis of cold scintiscan defects.Thyroid,2002,12(4):305-311.
[19]	Franklyn JA. The management of hyperthyroidism.N Engl J Med,1994,330(24):1731-1738.
[20]	邢家骝.主编.131碘治疗甲状腺疾病.北京:人民卫生出版社,2002.265-267.
[21]	Gittoes NJ,Franklyn JA. Current treatment guidelines.Drugs,1998,55(4):543-553.
[22]	Abraham P,Avenell A,Park GM,et al. A systematic review of drug therapy for Graves' hyperthyroidism.Eur J Endocrinol,2005,153(4):489-498.
[23]	Andrade VA,Gross JL,Maia AL. Radioactive iodine therapy in Graves' hyperthyroidism.Arq Bras Endocrinol Metabol,2004,48(1):159-165.
[24]	Reiners C. Radioiodine therapy for Graves' disease:problems and new developments.Z Arztl Fortbild Qualitatssich,2004,98(suppl 5):55-62.
[25]	Azizi F,Ataie L,Hedayati M,et al. Effect of long-term continuous methimazole treatment of hyperthyroidism:comparison with radioiodine.Eur J Endocrinol,2005,152(5):695-701.

[1]	苏莉 , 陈璟 , 赵明 . ¹³¹I治疗男性甲状腺亢进症周期性麻痹的临床观察:与抗甲状腺药物治疗比较. 国际放射医学核医学杂志, 2007, 31(6): 366-369.
[2]	孟召伟 , 谭建 . 解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南. 国际放射医学核医学杂志, 2011, 35(4): 193-201. doi: 10.3760/cma.j.issn.1673-4114.2011.04.001
[3]	王长修 . 甲状腺功能亢进症患者再次¹³¹I治疗的给药剂量对比研究. 国际放射医学核医学杂志, 2009, 33(3): 182-183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.016
[4]	孙琦婷 , 赵德善 . Graves病甲状腺功能亢进症与血糖代谢. 国际放射医学核医学杂志, 2010, 34(3): 143-147. doi: 10.3760/cma.j.issn.1673-4114.2010.03.004
[5]	潘香颖 , 李慧贞 . 甲状腺功能亢进症伴肝功能受损的¹³¹I治疗疗效. 国际放射医学核医学杂志, 2009, 33(3): 179-180. doi: 10.3760/cma.j.issn.1673-4114.2009.03.013
[6]	冯菲 , 赵德善 . ¹³¹I治疗青少年儿童甲状腺功能亢进症. 国际放射医学核医学杂志, 2009, 33(3): 171-174,183. doi: 10.3760/cma.j.issn.1673-4114.2009.03.011
[7]	汤建林 , 李玉莹 , 高柳艳 , 唐秀萍 , 胡红永 . 甲状腺功能亢进症治疗方法的比较和选择. 国际放射医学核医学杂志, 2009, 33(3): 175-178. doi: 10.3760/cma.j.issn.1673-4114.2009.03.012
[8]	王越 , 晋建华 , 李思进 , 刘建中 , 武志芳 , 陆克义 , 李江萍 . 甲状腺24h摄碘率与¹³¹I治疗Graves甲亢疗效相关性研究. 国际放射医学核医学杂志, 2015, 39(6): 442-446. doi: 10.3760/cma.j.issn.1673-4114.2015.06.002
[9]	郭坤 , 高蕊 , 于燕 , 刘岩 , 杨爱民 . 表皮生长因子受体基因表达与甲状腺功能亢进症¹³¹I治疗预后的关系. 国际放射医学核医学杂志, 2015, 39(1): 4-8. doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
[10]	苑丽丽 , 张阳 , 樊琳琳 , 黄承明 , 谭建 . 甲巯咪唑致粒细胞缺乏症2例. 国际放射医学核医学杂志, 2014, 38(5): 347-348. doi: 10.3760/cma.j.issn.1673-4114.2014.05.016